|
Cardiovascular Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Compared to CAC = 0, individuals with CAC 1-10 had an increased multivariable-adjusted risk of CVD death only under age 40.
|
31784032 |
2020 |
|
Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Adjusted multivariable analysis, compared to CAC-0, HR for all-cause mortality associated with CAC 1-99, 100-299 and ≫300 were 1.74(95% CI 0.65, 4.63, P-0.20), 5.54(95% CI 2.16, 14.22, P ≪ 0.001) and 5.75(95% CI 2.30, 14.37, P ≪ 0.001) in females with DM respectively; in males with DM HR associated with CAC 1-99, 100-299 and ≫300 were 1.87(95% CI 0.95, 3.66, P-0.06), 2.15(95% CI 1.05, 4.38, P-0.035) and 2.60(95% CI 1.34, 5.0, P-0.004), respectively.
|
31278061 |
2019 |
|
Hypertensive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Each 1-unit increase in ln(CAC+1) was independently associated with a 12% higher risk of hypertension (95% confidence interval [CI] 9% to 16%).
|
29174140 |
2018 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The relative adjusted subhazard ratio (aSHR) for CAC 1 to 100, 101 to 400, and >400 was 2.2, 3.8, and 5.9 for MI; 1.2, 1.4, and 1.9 for stroke; 1.4, 2.0, and 2.8 for MACE; and 1.2, 1.5 and 2.1 for death (p < 0.0001).
|
29153576 |
2018 |
|
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The relative adjusted subhazard ratio (aSHR) for CAC 1 to 100, 101 to 400, and >400 was 2.2, 3.8, and 5.9 for MI; 1.2, 1.4, and 1.9 for stroke; 1.4, 2.0, and 2.8 for MACE; and 1.2, 1.5 and 2.1 for death (p < 0.0001).
|
29153576 |
2018 |
|
Adenoma of large intestine
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the adjusted odds ratios (95% confidence interval) for any CRA comparing participants with CAC 1 to 100 and CAC>100 with those with no CAC were 1.26 (1.00-1.6) and 2.07 (1.31-3.26), respectively.
|
28471937 |
2018 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among evaluated risk factors, age [odds ratio (OR) 1.04, 95% confidence interval (CI) 1.02-1.07, <i>p</i><0.001], current smoking status (OR 3.12, 95% CI 1.82-5.34, <i>p</i><0.001), and CAC 1-9 (OR 1.80, 95% CI 1.08-3.00, <i>p</i>=0.024) were significantly associated with moderate CAD.
|
31250575 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
For example, among those with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, respectively, we found increasing hazard ratios for events with CAC 1 to 100 (1.7 [95% confidence interval, 1.0-2.6] or 2.0 [1.1-3.8]) and CAC >100 (3.0 [1.8-5.0] or 5.7 [2.9-11.0]), all relative to CAC=0.
|
27881560 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We demonstrated that CAC1 is over-expressed in malignant tumors, and cellular CAC1 depletion resulted in cancer growth suppression.
|
22903020 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Cox models were used to obtain hazard ratios according to CAC category, or per 1 SD log2[CAC+1], adjusted for vascular risk factor, APOE-ε4, with or without exclusion of interim stroke or cardiovascular disease.
|
28465455 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
We noted a significantly increased risk of CHD [hazard ratio (HR): 2.6 (1.5-4.3)] and CVD [HR: 2.3 (1.8-2.9)] mortality per unit increase in In (CAC + 1).
|
31486775 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that BCLP might be associated with cell morphology and a regulation of growth pattern of tumor.
|
11394883 |
2001 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that miR-199a-5p can regulate CAC1 and function as a tumor suppressor in colorectal cancer.
|
22903020 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
BCLP was detected in 47 of 126 cases (37%) including 32 AC (44%), 10 SCC 925%), two ASC (40%), and three LCC (38%).
|
7590697 |
1995 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our study provides the first evidence that CAC1, associated with LSD1, functions as an ERα corepressor, implicating a potential antitumor target in ERα-positive breast cancer.
|
23178685 |
2013 |
|
Malignant tumor of cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |
|
Cleft Palate
|
0.010 |
Biomarker
|
disease |
BEFREE |
More than half (55%, n = 36) were isolated cleft palates, and 35% (n = 23) were BCLPs.
|
29437500 |
2018 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We noted a significantly increased risk of CHD [hazard ratio (HR): 2.6 (1.5-4.3)] and CVD [HR: 2.3 (1.8-2.9)] mortality per unit increase in In (CAC + 1).
|
31486775 |
2019 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
1 SD higher log2[CAC+1] was associated with 24% (95% confidence interval, 8%-41%; <i>P</i>=0.002) increase in dementia risk.
|
28465455 |
2017 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |